Literature DB >> 19609004

Potentiation of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation of ceramide metabolism.

Kristin Gustafsson1, Birgitta Sander, Jacek Bielawski, Yusuf A Hannun, Jenny Flygare.   

Abstract

Ceramide levels are elevated in mantle cell lymphoma (MCL) cells following treatment with cannabinoids. Here, we investigated the pathways of ceramide accumulation in the MCL cell line Rec-1 using the stable endocannabinoid analogue R(+)-methanandamide (R-MA). We further interfered with the conversion of ceramide into sphingolipids that promote cell growth. Treatment with R-MA led to increased levels of ceramide species C16, C18, C24, and C(24:1) and transcriptional induction of ceramide synthases (CerS) 3 and 6. The effects were attenuated using SR141716A, which has high affinity to cannabinoid receptor 1 (CB1). The CB1-mediated induction of CerS3 and CerS6 mRNA was confirmed using Win-55,212-2. Simultaneous silencing of CerS3 and CerS6 using small interfering RNA abrogated the R-MA-induced accumulation of C16 and C24. Inhibition of either of the enzymes serine palmitoyl transferase, CerS, and dihydroceramide desaturase within the de novo ceramide pathway reversed ceramide accumulation and cell death induced by R-MA treatment. To enhance the cytotoxic effect R-MA, sphingosine kinase-1 and glucosylceramide synthase, enzymes that convert ceramide to the pro-proliferative sphingolipids sphingosine-1-phospate and glucosylceramide, respectively, were inhibited. Suppression of either enzyme using inhibitors or small interfering RNA potentiated the decreased viability, induction of cell death, and ceramide accumulation induced by R-MA treatment. Our findings suggest that R-MA induces cell death in MCL via CB1-mediated up-regulation of the de novo ceramide synthesis pathway. Furthermore, this is the first study were the cytotoxic effect of a cannabinoid is enhanced by modulation of ceramide metabolism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19609004      PMCID: PMC3077284          DOI: 10.1158/1541-7786.MCR-08-0361

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

Review 1.  Biologically active sphingolipids in cancer pathogenesis and treatment.

Authors:  Besim Ogretmen; Yusuf A Hannun
Journal:  Nat Rev Cancer       Date:  2004-08       Impact factor: 60.716

2.  Quantitative measurement of different ceramide species from crude cellular extracts by normal-phase high-performance liquid chromatography coupled to atmospheric pressure ionization mass spectrometry.

Authors:  Benjamin J Pettus; Bart-Jan Kroesen; Zdizslaw M Szulc; Alicia Bielawska; Jacek Bielawski; Yusuf A Hannun; Mark Busman
Journal:  Rapid Commun Mass Spectrom       Date:  2004       Impact factor: 2.419

3.  BcR-induced apoptosis involves differential regulation of C16 and C24-ceramide formation and sphingolipid-dependent activation of the proteasome.

Authors:  Bart-Jan Kroesen; Susan Jacobs; Benjamin J Pettus; Hannie Sietsma; Jan Willem Kok; Yusuf A Hannun; Lou F M H de Leij
Journal:  J Biol Chem       Date:  2003-02-10       Impact factor: 5.157

4.  Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas.

Authors:  Serap Koybasi; Can E Senkal; Kamala Sundararaj; Stefka Spassieva; Jacek Bielawski; Walid Osta; Terry A Day; James C Jiang; S Michal Jazwinski; Yusuf A Hannun; Lina M Obeid; Besim Ogretmen
Journal:  J Biol Chem       Date:  2004-08-17       Impact factor: 5.157

Review 5.  Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism.

Authors:  Kentaro Hanada
Journal:  Biochim Biophys Acta       Date:  2003-06-10

6.  Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.

Authors:  Edward Norris-Cervetto; Richard Callaghan; Frances M Platt; Raymond A Dwek; Terry D Butters
Journal:  J Biol Chem       Date:  2004-07-19       Impact factor: 5.157

7.  Mass spectrometric analysis of ceramide perturbations in brain and fibroblasts of mice and human patients with peroxisomal disorders.

Authors:  Benjamin J Pettus; Myriam Baes; Mark Busman; Yusuf A Hannun; Paul P Van Veldhoven
Journal:  Rapid Commun Mass Spectrom       Date:  2004       Impact factor: 2.419

8.  Ceramide metabolite, not intact ceramide molecule, may be responsible for cellular toxicity.

Authors:  Kou-Yi Tserng; Ronda L Griffin
Journal:  Biochem J       Date:  2004-06-15       Impact factor: 3.857

9.  Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells.

Authors:  Yong-Yu Liu; Tie Yan Han; Jing Yuan Yu; Arie Bitterman; Ahn Le; Armando E Giuliano; Myles C Cabot
Journal:  J Lipid Res       Date:  2004-02-16       Impact factor: 5.922

10.  Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53.

Authors:  Tarek A Taha; Walid Osta; Lina Kozhaya; Jacek Bielawski; Korey R Johnson; William E Gillanders; Ghassan S Dbaibo; Yusuf A Hannun; Lina M Obeid
Journal:  J Biol Chem       Date:  2004-02-26       Impact factor: 5.157

View more
  23 in total

Review 1.  Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics.

Authors:  Alfred H Merrill
Journal:  Chem Rev       Date:  2011-09-26       Impact factor: 60.622

2.  Cannabinoid Receptor-2 Regulates Embryonic Hematopoietic Stem Cell Development via Prostaglandin E2 and P-Selectin Activity.

Authors:  Virginie Esain; Wanda Kwan; Kelli J Carroll; Mauricio Cortes; Sarah Y Liu; Gregory M Frechette; Lea M V Sheward; Sahar Nissim; Wolfram Goessling; Trista E North
Journal:  Stem Cells       Date:  2015-05-26       Impact factor: 6.277

Review 3.  The role of G protein-coupled receptors in lymphoid malignancies.

Authors:  Adrienne Nugent; Richard L Proia
Journal:  Cell Signal       Date:  2017-08-09       Impact factor: 4.315

Review 4.  Sphingolipid signaling and hematopoietic malignancies: to the rheostat and beyond.

Authors:  Kenneth C Loh; Dianna Baldwin; Julie D Saba
Journal:  Anticancer Agents Med Chem       Date:  2011-11       Impact factor: 2.505

Review 5.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

Review 6.  Ceramide synthases at the centre of sphingolipid metabolism and biology.

Authors:  Thomas D Mullen; Yusuf A Hannun; Lina M Obeid
Journal:  Biochem J       Date:  2012-02-01       Impact factor: 3.857

Review 7.  Insights into the effects of the endocannabinoid system in cancer: a review.

Authors:  Ana Isabel Fraguas-Sánchez; Cristina Martín-Sabroso; Ana Isabel Torres-Suárez
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

Review 8.  Mammalian ceramide synthases.

Authors:  Michal Levy; Anthony H Futerman
Journal:  IUBMB Life       Date:  2010-05       Impact factor: 3.885

Review 9.  Sphingolipids and cancer: ceramide and sphingosine-1-phosphate in the regulation of cell death and drug resistance.

Authors:  Suriyan Ponnusamy; Marisa Meyers-Needham; Can E Senkal; Sahar A Saddoughi; David Sentelle; Shanmugam Panneer Selvam; Arelis Salas; Besim Ogretmen
Journal:  Future Oncol       Date:  2010-10       Impact factor: 3.404

Review 10.  Systematic review of the literature on clinical and experimental trials on the antitumor effects of cannabinoids in gliomas.

Authors:  Francisco Carlos Machado Rocha; Jair Guilherme Dos Santos Júnior; Sergio Carlos Stefano; Dartiu Xavier da Silveira
Journal:  J Neurooncol       Date:  2013-10-20       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.